GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adynxx Inc (FRA:HL1C) » Definitions » Notes Receivable

Adynxx (FRA:HL1C) Notes Receivable : €0.00 Mil (As of Sep. 2019)


View and export this data going back to 1998. Start your Free Trial

What is Adynxx Notes Receivable?

Adynxx's Notes Receivable for the quarter that ended in Sep. 2019 was €0.00 Mil.


Adynxx Notes Receivable Historical Data

The historical data trend for Adynxx's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adynxx Notes Receivable Chart

Adynxx Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Adynxx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Adynxx Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Adynxx Notes Receivable Related Terms

Thank you for viewing the detailed overview of Adynxx's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Adynxx (FRA:HL1C) Business Description

Traded in Other Exchanges
N/A
Address
100 Pine Street, Suite 500, San Francisco, CA, USA, 94111
Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.

Adynxx (FRA:HL1C) Headlines

No Headlines